Articles

This instrument is made under section 39 of the current Poisons Standard.

This instrument is made under section 39 of the current Poisons Standard.

We are providing a 12-month period of labelling exemptions for signal words for certain Pharmacy medicine and Pharmacist Only medicine products.

Following our Essential Principles presentations on 11-12 September 2024, we have collated questions asked into themes to simplify finding information of relevance to you.

We have accepted an enforceable undertaking from 2San Pty Ltd in relation to breaches of the Therapeutic Goods Act 1989. This relates to the company's unlawful import and supply of medical devices.

The company imported medical devices not included in the Australian Register of Therapeutic Goods. They supplied these devices to a national retailer, who then sold them to the public.

This instrument is the Therapeutic Goods (Poisons Standard) (Benzylpenicillin—Seqirus) Approval 2024.

Find out about changes to choline salicylate access, starting from October 2023.

Stay updated about the commencement of MDMA and psilocybin for the treatment of certain mental illnesses.

The TGA has published a final decision to reduce the maximum size of packs for various paracetamol products.

From 1 June 2023, prescribing of oral ivermectin for ‘off-label’ uses will no longer be limited to specialists such as dermatologists, gastroenterologists and infectious diseases specialists.

From 1 July 2023, authorised psychiatrists can prescribe psychedelic medicines to people with specific mental health conditions under strict controls.

The TGA has today published an interim decision to reduce the maximum pack sizes for various paracetamol products.

From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions.

The TGA has published an independent expert report examining the incidence of serious injury and death from intentional paracetamol overdose.

The TGA has approved the first two nasal combination self-tests (for use at home) that detect both COVID-19 and influenza viral infections in humans.

This labelling exemption is granted under section 1.1(3) of Part 2 of the current Poisons Standard.

Today the TGA announced a final decision to down-schedule certain low dose cannabidiol (CBD) preparations